Skip to main content

Anti-Microbial & Anti-Viral Testing

Discovery Services

Select Service Type

ANTI-MICROBIAL TESTING

  • Estimation of Microbial LoadDRF/CB/AMT-01

    Estimation of Microbial Load to evaluate Microbial Load using panel selected, measuring Colony count.

    • Cell Model

      Panel on request

    • End Point

      Colony count

    • Reference Drugs

      Based on the microbe selected

    • Relevance

      Microbial Load
  • Minimum Inhibitory Concentration (MIC)/ Minimum Bactericidal Concentration (MBC)/ Zone of inhibition (ZOI)DRF/CB/AMT-02

    Minimum Inhibitory Concentration (MIC)/ Minimum Bactericidal Concentration (MBC)/ Zone of inhibition (ZOI) to evaluate antimicrobial effectiveness using panel selected, measuring MIC/ MBC value.

    • Cell Model

      Panel on request

    • End Point

      MIC/ MBC value

    • Reference Drugs

      Based on the microbe selected

    • Relevance

      Antimicrobial Effectiveness
  • Determination of Anti-microbial Potential (By Minimum Inhibitory Concentration (MIC)/ Minimum Bactericidal Concentration (MBC)/ Method)DRF/CB/AMT-03

    Determination of Anti-microbial Potential (By Minimum Inhibitory Concentration (MIC)/ Minimum Bactericidal Concentration (MBC)/ Method) using panel selected to study Antimicrobial Potential.

    • Cell Model

      Panel on request

    • End Point

      MIC/ MBC value

    • Reference Drugs

      Based on the microbe selected

    • Relevance

      Antimicrobial Potential

COVID SCREENS

  • Cytopathic effect (CPE) against SARS-COV-2DRF/CB/CS-01

    Cytopathic effect (CPE) against SARS-COV-2 to evaluate Anti-viral using SARS-COV2/ Vero76, measuring CPE activity.

    • Cell Model

      SARS-COV2/ Vero76

    • End Point

      CPE activity

    • Reference Drugs

      Remdesivir

    • Relevance

      Anti-viral
  • Virucidal effect against SARS-COV-2DRF/CB/CS-02

    Virucidal effect against SARS-COV-2 to evaluate disinfectant effect using SARS-COV2/ Vero76, measuring virucidal activity.

    • Cell Model

      SARS-COV2/ Vero76

    • End Point

      Virucidal activity

    • Reference Drugs

      Alcohol

    • Relevance

      Disinfectant effect
  • Spike-ACE2 interaction assayDRF/CB/CS-03

    Spike-ACE2 interaction assay to evaluate Anti-viral using cell-free assay, measuring Spike-ACE 2 interaction inhibition.

    • Cell Model

      Cell-free

    • End Point

      Spike-ACE 2 interaction inhibition

    • Reference Drugs

      Emodin

    • Relevance

      Anti-viral
  • Cytokines inhibition in immune cells against cytokine storm induced by native spike proteinDRF/CB/CS-04

    Cytokines inhibition in immune cells against cytokine storm induced by native spike protein to evaluate Anti-viral using Human Monocytes (THP-1), measuring cytokine inhibition.

    • Cell Model

      Human Monocytes (THP-1)

    • End Point

      Cytokine inhibition

    • Reference Drugs

      Dexamethasone & HCQ

    • Relevance

      Anti-viral
  • Cytokines inhibition in immune cells against cytokine storm induced by mutant spike proteinDRF/CB/CS-05

    Cytokines inhibition in immune cells against cytokine storm induced by mutant spike protein to evaluate anti-viral using Human Monocytes (THP-1), measuring cytokine inhibition.

    • Cell Model

      Human Monocytes (THP-1)

    • End Point

      Cytokine inhibition

    • Reference Drugs

      Dexamethasone & HCQ

    • Relevance

      Anti-viral
  • Modulation of angiotensin receptor (AT1R)DRF/CB/CS-06

    Modulation of angiotensin receptor (AT1R) to evaluate Anti-viral using Receptor over-expressing cells, measuring agonist/ antagonist activity.

    • Cell Model

      Receptor over-expressing cells

    • End Point

      agonist/ antagonist activity

    • Reference Drugs

      Telmisartan

    • Relevance

      Anti-viral
  • Inhibition of NAK kinasesDRF/CB/CS-07

    Inhibition of NAK kinases to evaluate Anti-viral using Receptor over-expressing cells, measuring Kinase activity.

    • Cell Model

      Receptor over-expressing cells

    • End Point

      Kinase activity

    • Reference Drugs

      Barcitinib

    • Relevance

      Anti-viral
  • Inhibition of proteases (Furin, DPP4, Cathepsin, 3CL, TMPRSS2)DRF/CB/CS-08

    Inhibition of proteases (Furin, DPP4, Cathepsin, 3CL, TMPRSS2) to evaluate Anti-viral using Cell-free, measuring Enzyme activity.

    • Cell Model

      Cell-free

    • End Point

      Enzyme activity

    • Reference Drugs

      Based on the protease selected

    • Relevance

      Anti-viral
  • Lysosomal/endosomal alkalinizationDRF/CB/CS-09

    Lysosomal/endosomal alkalinization to evaluate Anti-viral using Human Lung Cells (A549), measuring Lysosomal/endosomal alkalinization.

    • Cell Model

      Human Lung Cells (A549)

    • End Point

      Lysosomal/endosomal alkalinization

    • Reference Drugs

      Sodium bicarbonate

    • Relevance

      Anti-viral
  • Expression levels of ACE2 DRF/CB/CS-10

    Expression levels of ACE2 to evaluate Anti-viral using Human Lung Cells (A549), measuring ACE2 receptor levels.

    • Cell Model

      Human Lung Cells (A549)

    • End Point

      ACE2 receptor levels

    • Reference Drugs

      MLN4760

    • Relevance

      Anti-viral
  • ATPase activityDRF/CB/CS-11

    ATPase activity to evaluate Anti-viral using Human Lung Cells (A549), measuring ATPase activity.

    • Cell Model

      Human Lung Cells (A549)

    • End Point

      ATPase activity

    • Reference Drugs

      Sodium bicarbonate

    • Relevance

      Anti-viral

ANTIVIRAL

  • SARS CoV2 Spike protein induced Lung inflammation model PCY/COV-01

    SARS-CoV-2 spike protein-induced lung inflammation model in mice, assessing lung gross pathology, cytokine levels in BALF, and lung histopathology.

    • Animal Model

      BALB/c Mice

    • End Point

      Gross pathology of Lung, Cytokine (IL-1β, IFN-γ and TNF-α etc..) in BALF, Histopathological investigation of Lung

    • Reference Drugs

      Dexamethasone
  • In-vivo efficacy of test item against intranasal SARS-CoV2 model PCY/COV-02

    In-vivo efficacy of test item against intranasal SARS-CoV-2 model in hamsters, measuring clinical signs, body weight, lung viral titer, and lung histopathology.

    • Animal Model

      Hamster

    • End Point

      Clinical Sign, Body Weight change, Lung viral titer, Cytokine gene in Spleenocyte, Histopathology of lung

    • Reference Drugs

      Remdesivir
  • In-vivo efficacy of test item against intranasal influenza virus model PCY/COV-03

    In-vivo efficacy of test item against intranasal influenza virus model in mice, assessing clinical score, survival, viral load in the lung, and histopathology.

    • Animal Model

      BALB/c Mice

    • End Point

      Clinical Score, Body Weight Change,Survival,Viral load in lung,Nasal Wash,Cytokine level in BALF & Plasma, Histopathology of lung

    • Reference Drugs

      Oseltamivir